Analyst Rating Update on GW Pharmaceuticals Plc (GWPH)

GW Pharmaceuticals Plc (NASDAQ:GWPH) : 7 analysts are covering GW Pharmaceuticals Plc (NASDAQ:GWPH) and their average rating on the stock is 1.64, which is read as a Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. GW Pharmaceuticals Plc (NASDAQ:GWPH) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock.

GW Pharmaceuticals Plc (NASDAQ:GWPH) : 6 Wall Street analysts covering GW Pharmaceuticals Plc (NASDAQ:GWPH) believe that the average level the stock could reach for the short term is $151.17. The maximum price target given is $181 and the minimum target for short term is around $130, hence the standard deviation is calculated at $19.04.

For the current week, the company shares have a recommendation consensus of Buy. Also, Cantor Fitzgerald initiates coverage on GW Pharmaceuticals Plc (NASDAQ:GWPH) The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency announces the price target to $181 per share. The rating by the firm was issued on June 2, 2016.

GW Pharmaceuticals Plc (NASDAQ:GWPH): stock turned positive on Tuesday. Though the stock opened at $89.99, the bulls momentum made the stock top out at $94.32 level for the day. The stock recorded a low of $88.59 and closed the trading day at $91.93, in the green by 3.89%. The total traded volume for the day was 984,070. The stock had closed at $88.49 in the previous days trading.

GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. The Companys product, Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain, the indication for the United States market.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.